Pipeline Integration Leaves Merck's Backbone As Cardiovascular, Infectious Disease
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Merck & Co.'s new late-stage pipeline, which integrates Schering-Plough's assets, positions it as a leader in cardiovascular disease and infectious disease drug development. Other therapeutic areas in the lineup include oncology, central nervous system disorders, diabetes and vaccines, and new opportunities in women's health